The Breast Cancer Liquid Biopsy Market was valued at USD 1.13 billion in 2023 and is expected to reach USD 2.37 billion by 2032, growing at a CAGR of 8.61% over the forecast period of 2024-2032. This report emphasizes liquid biopsy adoption and usage patterns driven by a growing interest in non-invasive diagnostic procedures and early detection of cancer. The research investigates reimbursement and coverage patterns geographically, with differences in healthcare policy affecting patient access to these tests. It also discusses pricing patterns of liquid biopsy tests, with technological improvements and economies of scale driving costs lower and expanding market reach. The report discusses ongoing research pipeline trends, which highlight innovations in circulating tumor DNA (ctDNA) testing and biomarker discovery that improve test precision. In addition, regulatory patterns and policy effects are defining market growth, as governments and health authorities collaborate to standardize guidelines and affirm the clinical validity of liquid biopsy uses.
The U.S. Breast Cancer Liquid Biopsy Market was valued at USD 0.33 billion in 2023 and is expected to reach USD 0.63 billion by 2032, growing at a CAGR of 7.4% over the forecast period of 2024-2032. In the United States, the breast cancer liquid biopsy market is gaining pace because of greater FDA approvals, expanding insurance coverage, and increased investments in precision oncology, thus making the tests more accessible for early-stage and metastatic breast cancer surveillance.
Market Dynamics
Drivers
The growing shift toward precision oncology has significantly driven the adoption of liquid biopsy in breast cancer management.
Liquid biopsy provides non-invasive, real-time monitoring of tumors, diminishing the necessity for invasive tissue biopsies. According to research, more than 70% of oncologists now include liquid biopsy as an important tool to guide targeted therapy. The elevated specificity and sensitivity of liquid biopsy, especially cfDNA-based testing, have made it a necessary element in choosing treatment and tracking minimal residual disease (MRD). Also, improved NGS technology and artificial intelligence (AI) in diagnostics have improved the tests' accuracy and dependability. Growth in companion diagnostics for precision medicines like HER2 and BRCA mutation tests has further accelerated demand. Research promotion by governments for liquid biopsies and enhanced FDA approvals for liquid biopsy-based tests are further fueling adoption. For instance, FDA-approved Guardant360 and FoundationOne Liquid CDx have widened the clinical use of the market. The patient demand for non-invasive methods, combined with an increase in late-stage breast cancer, is further driving demand. Moreover, the cost-effectiveness of a liquid biopsy over surgical biopsies makes it more accessible, even in resource-constrained and high-income environments.
Restraints
The breast cancer liquid biopsy market faces regulatory and standardization challenges, which hinder widespread adoption.
The absence of globally harmonized standards for liquid biopsy testing generates inconsistencies in clinical use. Regulatory agencies such as the FDA and EMA place strict validation requirements, hindering approvals of novel liquid biopsy technologies. In contrast to the conventional tissue biopsies that possess established diagnostic criteria, liquid biopsy tests do not have standardized reference values, resulting in differences in test outcomes across laboratories and platforms. Moreover, anxiety about false positives and false negatives causes oncologists to doubt, which restricts its application in clinical decision-making. Reimbursement issues also limit market expansion since most insurance providers do not cover liquid biopsy tests, making them unavailable to a lot of patients. For example, Medicare only covers particular indications of liquid biopsy, restricting its extensive clinical value. Highly expensive advanced sequencing technologies also limit adoption among the poor. In addition, technical difficulties in isolating and analyzing circulating biomarkers, particularly CTCs, create limitations in obtaining precise results. The integration of these regulatory and technical hurdles hinders the clinical adoption of liquid biopsy, making it unable to completely replace conventional diagnostic techniques in breast cancer treatment.
Opportunities
The expanding applications of liquid biopsy beyond late-stage diagnosis present a major growth opportunity for the market.
Conventionally employed for disease tracking and directing aimed therapies, liquid biopsy is increasingly being explored in early detection and screening schemes. The rise of multi-cancer early detection (MCED), led by key players such as Grail's Galleri test, underscores the prospects of liquid biopsy in the pre-symptomatic detection of breast cancer. Studies indicate that detection of early-stage breast cancer with the help of cfDNA has attained a sensitivity of more than 85% and thus offers a significant substitute to mammography. Additionally, the combination of AI and machine learning within liquid biopsy is improving the precision in detecting biomarkers, further enhancing clinical results. The increased partnerships among biotech firms and pharmaceutical companies for companion diagnostic development also offer a rich opportunity. For instance, the collaboration between Illumina and Roche is focused on driving NGS-based liquid biopsy solutions forward. Besides, the growth of home-based liquid biopsy test kits, spurred on by convenience demands from consumers, is an unexploited market potential. As continued research into extracellular vesicles (EVs) and epigenetic markers continues to develop, new biomarkers will further expand the applications of liquid biopsy, such that it becomes a cornerstone in personalized breast cancer management.
Challenges
One of the biggest challenges facing the breast cancer liquid biopsy market is the technological and data interpretation limitations that impact clinical reliability.
Although a liquid biopsy is a non-invasive method, its performance can be hampered by the presence of low biomarker levels in blood. According to studies, tumor-derived cfDNA comprises less than 1% of the total circulating DNA, rendering it extremely difficult to detect. Further, tumor-derived cfDNA discrimination from cell-free DNA is also a cumbersome task, causing false negatives. Another major concern is the absence of standardization in bioinformatics pipelines since different sequencing platforms and algorithms yield different interpretations of genetic changes. This variability is a cause of concern for oncologists regarding the reproducibility of test results. Additionally, liquid biopsy is not able to differentiate between active and latent tumors, and hence, it is challenging to ascertain real-time disease progression. Data privacy and ethical issues around genomic sequencing also present challenges, with regulatory bodies enforcing stringent data protection regulations. The expense of incorporating AI-powered analytics into liquid biopsy platforms is also prohibitively high, limiting its scalability. Finally, the lack of awareness and training among oncologists and healthcare professionals in interpreting liquid biopsy data slows down widespread clinical uptake, presenting a bottleneck for market expansion.
By Biomarkers
The circulating cell-free DNA (cfDNA) segment dominated the Breast Cancer Liquid Biopsy Market in 2023 with a 50.7% revenue share. This is powered by the increasing clinical adoption of cfDNA-based liquid biopsies for the detection of genetic mutations and minimal residual disease (MRD) monitoring. The high specificity and sensitivity of cfDNA in detecting tumor-specific changes have made it a biomarker of choice in the diagnosis and treatment planning of breast cancer. Moreover, improvements in next-generation sequencing (NGS) technology have further cemented its position in informing targeted therapies.
The circulating tumor cells (CTCs) space is anticipated to see the highest growth in the future. Growing interest in real-time monitoring of cancer and the role that CTCs play in evaluating tumor heterogeneity are the key drivers of this growth. In contrast to cfDNA, whose contribution is fragmented genetic material, CTCs can present information related to tumor biology and thus enable improved monitoring of treatment response. The increasing investment in research for the improvement of CTC detection and analysis techniques is also anticipated to fuel its adoption.
By Application
The treatment selection segment was the top application in 2023, with 48.4% of the entire market revenue. Liquid biopsy has a significant function in detecting mutations that inform customized treatment plans and, thus, is needed for choosing targeted treatments like hormone therapy or HER2 inhibitors. The growing appeal for precision medicine and companion diagnostics, particularly for metastatic breast cancers, has backed up the trend toward using liquid biopsy in determining the best care treatment. Secondarily, due to its minimally invasive quality, it poses less inconvenience when used compared to classical tissue biopsy procedures, augmenting its marketplace supremacy.
The early detection/screening segment is anticipated to develop at a high rate because of the increasing focus on the diagnosis of cancer at the early stages. Liquid biopsy provides a promising option to mammography and tissue biopsies through the identification of cancer-associated genetic mutations before the onset of clinical symptoms. The increase in awareness campaigns, along with continued research into multi-cancer early detection (MCED) technologies, is projected to propel the growth of liquid biopsy in screening applications. In addition, the growing use of liquid biopsy in standard cancer risk assessment programs is likely to drive its uptake.
Regional Analysis
North America led the breast cancer liquid biopsy market in 2023, fueled by sophisticated healthcare infrastructure, high-precision oncology adoption rates, and robust regulatory encouragement. The region holds a significant portion of liquid biopsy tests globally, with the U.S. taking the lead due to the concentration of dominant market players such as Guardant Health, Exact Sciences, and Bio-Rad Laboratories. FDA approvals of liquid biopsy-based companion diagnostics have spurred clinical adoption, propelling the U.S. as a global market leader in breast cancer liquid biopsy applications. Further, the growing incidence of breast cancer, with more than 297,000 new cases reported in the U.S. in 2023, has boosted demand for non-invasive diagnostic tests.
Nonetheless, the Asia-Pacific is the highest-growing region projected to see faster growth with accelerating cancer incidence, developing healthcare infrastructure, and augmenting awareness related to early detection of cancer. Investment in research related to liquid biopsy is burgeoning in the Asia-Pacific region, with China, Japan, and India being leaders. Liquid biopsy uptake has amplified notably in China, with enterprises such as Burning Rock Biotech and BGI Genomics catalyzing market expansion in local areas. The escalating government backing for precision medicine projects, combined with rising healthcare expenditures, is likely to drive Asia-Pacific's market at the fastest growth rate in the forecast period.
The Menarini Group: DEPArray system
NeoGenomics Laboratories: Liquid biopsy assays for breast cancer diagnostics
F. Hoffmann-La Roche Ltd.: Cobas EGFR Mutation Test v2
Myriad Genetics, Inc.: MyChoice HRD test
Thermo Fisher Scientific, Inc.: Ion Torrent Oncomine Pan-Cancer Cell-Free Assay
QIAGEN: QIAamp Circulating Nucleic Acid Kit
Biocept, Inc.: Target Selector liquid biopsy assays
Sysmex Corporation: OncoBEAM tests
Fluxion Biosciences, Inc.: IsoFlux Liquid Biopsy System
Epic Sciences, Inc.: Oncotype DX AR-V7 Nucleus Detect test
Recent Developments
In Oct 2024, Foundation Medicine, Inc. received FDA approval for FoundationOne Liquid CDx as a companion diagnostic for Itovebi (inavolisib) in combination with palbociclib (Ibrance) and fulvestrant. This approval supports the treatment of HR-positive, HER2-negative, PIK3CA-mutated metastatic breast cancer, developed by Genentech (Roche Group), for patients with endocrine-resistant disease following recurrence after adjuvant endocrine therapy.
In April 2024, Bio-Rad Laboratories launched the ddPLEX ESR1 Mutation Detection Kit, its first ultrasensitive multiplexed digital PCR assay for breast cancer mutation detection. This expands its Droplet Digital PCR (ddPCR) portfolio, enhancing mutation detection, therapy selection, and disease monitoring in oncology research.
| Report Attributes | Details |
|---|---|
| Market Size in 2023 | USD 1.13 billion |
| Market Size by 2032 | USD 2.37 billion |
| CAGR | CAGR of 8.61% From 2024 to 2032 |
| Base Year | 2023 |
| Forecast Period | 2024-2032 |
| Historical Data | 2020-2022 |
| Report Scope & Coverage | Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook |
| Key Segments | • By Biomarkers [Circulating Tumor Cells (CTCs), Circulating Cell-free DNA (cfDNA), Extracellular Vesicles (EVs), Other Circulating Biomarkers] • By Application [Early Detection/Screening, Diagnosis, Treatment Selection, Monitoring] |
| Regional Analysis/Coverage | North America (US, Canada, Mexico), Europe (Eastern Europe [Poland, Romania, Hungary, Turkey, Rest of Eastern Europe] Western Europe] Germany, France, UK, Italy, Spain, Netherlands, Switzerland, Austria, Rest of Western Europe]), Asia Pacific (China, India, Japan, South Korea, Vietnam, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (Middle East [UAE, Egypt, Saudi Arabia, Qatar, Rest of Middle East], Africa [Nigeria, South Africa, Rest of Africa], Latin America (Brazil, Argentina, Colombia, Rest of Latin America) |
| Company Profiles | The Menarini Group, NeoGenomics Laboratories, F. Hoffmann-La Roche Ltd., Myriad Genetics, Inc., Thermo Fisher Scientific, Inc., QIAGEN, Biocept, Inc., Sysmex Corporation, Fluxion Biosciences, Inc., and Epic Sciences, Inc. |
Ans: The Breast Cancer Liquid Biopsy market is anticipated to grow at a CAGR of 8.61% from 2024 to 2032.
Ans: The market is expected to reach USD 2.37 billion by 2032, increasing from USD 1.13 billion in 2023.
Ans: The growing shift toward precision oncology has significantly driven the adoption of liquid biopsy in breast cancer management.
Ans: The breast cancer liquid biopsy market faces regulatory and standardization challenges, which hinder widespread adoption.
Ans: North America dominated the Breast Cancer Liquid Biopsy market.
Table of contents
1. Introduction
1.1 Market Definition
1.2 Scope (Inclusion and Exclusions)
1.3 Research Assumptions
2. Executive Summary
2.1 Market Overview
2.2 Regional Synopsis
2.3 Competitive Summary
3. Research Methodology
3.1 Top-Down Approach
3.2 Bottom-up Approach
3.3. Data Validation
3.4 Primary Interviews
4. Market Dynamics Impact Analysis
4.1 Market Driving Factors Analysis
4.1.2 Drivers
4.1.2 Restraints
4.1.3 Opportunities
4.1.4 Challenges
4.2 PESTLE Analysis
4.3 Porter’s Five Forces Model
5. Statistical Insights and Trends Reporting
5.1 Liquid Biopsy Adoption and Utilization Trends (2023-2032)
5.2 Reimbursement and Coverage Trends (2023), by Region
5.3 Pricing Trends of Liquid Biopsy Tests (2023-2032)
5.4 Technological Advancements and Research Pipeline Trends
5.5 Regulatory Trends and Policy Impacts
6. Competitive Landscape
6.1 List of Major Companies, By Region
6.2 Market Share Analysis, By Region
6.3 Service Benchmarking
6.3.1 Service specifications and features
6.3.2 Pricing
6.4 Strategic Initiatives
6.4.1 Marketing and promotional activities
6.4.2 Distribution and Supply Chain Strategies
6.4.3 Expansion plans and new Service launches
6.4.4 Strategic partnerships and collaborations
6.5 Technological Advancements
6.6 Market Positioning and Branding
7. Breast Cancer Liquid Biopsy Market Segmentation, by Biomarkers
7.1 Chapter Overview
7.2 Circulating Tumor Cells (CTCs)
7.2.1 Circulating Tumor Cells (CTCs) Market Trends Analysis (2020-2032)
7.2.2 Circulating Tumor Cells (CTCs) Market Size Estimates and Forecasts to 2032 (USD Billion)
7.3 Circulating Cell-Free DNA (cfDNA)
7.3.1 Circulating Cell-Free DNA (cfDNA) Market Trends Analysis (2020-2032)
7.3.2 Circulating Cell-Free DNA (cfDNA) Market Size Estimates and Forecasts to 2032 (USD Billion)
7.4 Extracellular Vesicles (EVs)
7.4.1 Extracellular Vesicles (EVs) Market Trends Analysis (2020-2032)
7.4.2 Extracellular Vesicles (EVs) Market Size Estimates and Forecasts to 2032 (USD Billion)
7.5 Other Circulating Biomarkers
7.5.1 Other Circulating Biomarkers Market Trends Analysis (2020-2032)
7.5.2 Other Circulating Biomarkers Market Size Estimates and Forecasts to 2032 (USD Billion)
8. Breast Cancer Liquid Biopsy Market Segmentation, by Application
8.1 Chapter Overview
8.2 Early Detection/Screening
8.2.1 Early Detection/Screening Market Trends Analysis (2020-2032)
8.2.2 Early Detection/Screening Market Size Estimates and Forecasts to 2032 (USD Billion)
8.3 Diagnosis
8.3.1 Diagnosis Market Trends Analysis (2020-2032)
8.3.2 Diagnosis Market Size Estimates and Forecasts to 2032 (USD Billion)
8.4 Treatment Selection
8.4.1 Treatment Selection Market Trends Analysis (2020-2032)
8.4.2 Treatment Selection Market Size Estimates and Forecasts to 2032 (USD Billion)
8.5 Monitoring
8.5.1 Monitoring Market Trends Analysis (2020-2032)
8.5.2 Monitoring Market Size Estimates and Forecasts to 2032 (USD Billion)
9. Regional Analysis
9.1 Chapter Overview
9.2 North America
9.2.1 Trends Analysis
9.2.2 North America Breast Cancer Liquid Biopsy Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
9.2.3 North America Breast Cancer Liquid Biopsy Market Estimates and Forecasts, by Biomarkers (2020-2032) (USD Billion)
9.2.4 North America Breast Cancer Liquid Biopsy Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
9.2.5 USA
9.2.5.1 USA Breast Cancer Liquid Biopsy Market Estimates and Forecasts, by Biomarkers (2020-2032) (USD Billion)
9.2.5.2 USA Breast Cancer Liquid Biopsy Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
9.2.6 Canada
9.2.6.1 Canada Breast Cancer Liquid Biopsy Market Estimates and Forecasts, by Biomarkers (2020-2032) (USD Billion)
9.2.6.2 Canada Breast Cancer Liquid Biopsy Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
9.2.7 Mexico
9.2.7.1 Mexico Breast Cancer Liquid Biopsy Market Estimates and Forecasts, by Biomarkers (2020-2032) (USD Billion)
9.2.7.2 Mexico Breast Cancer Liquid Biopsy Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
9.3 Europe
9.3.1 Eastern Europe
9.3.1.1 Trends Analysis
9.3.1.2 Eastern Europe Breast Cancer Liquid Biopsy Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
9.3.1.3 Eastern Europe Breast Cancer Liquid Biopsy Market Estimates and Forecasts, by Biomarkers (2020-2032) (USD Billion)
9.3.1.4 Eastern Europe Breast Cancer Liquid Biopsy Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
9.3.1.5 Poland
9.3.1.5.1 Poland Breast Cancer Liquid Biopsy Market Estimates and Forecasts, by Biomarkers (2020-2032) (USD Billion)
9.3.1.5.2 Poland Breast Cancer Liquid Biopsy Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
9.3.1.6 Romania
9.3.1.6.1 Romania Breast Cancer Liquid Biopsy Market Estimates and Forecasts, by Biomarkers (2020-2032) (USD Billion)
9.3.1.6.2 Romania Breast Cancer Liquid Biopsy Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
9.3.1.7 Hungary
9.3.1.7.1 Hungary Breast Cancer Liquid Biopsy Market Estimates and Forecasts, by Biomarkers (2020-2032) (USD Billion)
9.3.1.7.2 Hungary Breast Cancer Liquid Biopsy Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
9.3.1.8 Turkey
9.3.1.8.1 Turkey Breast Cancer Liquid Biopsy Market Estimates and Forecasts, by Biomarkers (2020-2032) (USD Billion)
9.3.1.8.2 Turkey Breast Cancer Liquid Biopsy Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
9.3.1.9 Rest of Eastern Europe
9.3.1.9.1 Rest of Eastern Europe Breast Cancer Liquid Biopsy Market Estimates and Forecasts, by Biomarkers (2020-2032) (USD Billion)
9.3.1.9.2 Rest of Eastern Europe Breast Cancer Liquid Biopsy Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
9.3.2 Western Europe
9.3.2.1 Trends Analysis
9.3.2.2 Western Europe Breast Cancer Liquid Biopsy Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
9.3.2.3 Western Europe Breast Cancer Liquid Biopsy Market Estimates and Forecasts, by Biomarkers (2020-2032) (USD Billion)
9.3.2.4 Western Europe Breast Cancer Liquid Biopsy Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
9.3.2.5 Germany
9.3.2.5.1 Germany Breast Cancer Liquid Biopsy Market Estimates and Forecasts, by Biomarkers (2020-2032) (USD Billion)
9.3.2.5.2 Germany Breast Cancer Liquid Biopsy Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
9.3.2.6 France
9.3.2.6.1 France Breast Cancer Liquid Biopsy Market Estimates and Forecasts, by Biomarkers (2020-2032) (USD Billion)
9.3.2.6.2 France Breast Cancer Liquid Biopsy Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
9.3.2.7 UK
9.3.2.7.1 UK Breast Cancer Liquid Biopsy Market Estimates and Forecasts, by Biomarkers (2020-2032) (USD Billion)
9.3.2.7.2 UK Breast Cancer Liquid Biopsy Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
9.3.2.8 Italy
9.3.2.8.1 Italy Breast Cancer Liquid Biopsy Market Estimates and Forecasts, by Biomarkers (2020-2032) (USD Billion)
9.3.2.8.2 Italy Breast Cancer Liquid Biopsy Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
9.3.2.9 Spain
9.3.2.9.1 Spain Breast Cancer Liquid Biopsy Market Estimates and Forecasts, by Biomarkers (2020-2032) (USD Billion)
9.3.2.9.2 Spain Breast Cancer Liquid Biopsy Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
9.3.2.10 Netherlands
9.3.2.10.1 Netherlands Breast Cancer Liquid Biopsy Market Estimates and Forecasts, by Biomarkers (2020-2032) (USD Billion)
9.3.2.10.2 Netherlands Breast Cancer Liquid Biopsy Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
9.3.2.11 Switzerland
9.3.2.11.1 Switzerland Breast Cancer Liquid Biopsy Market Estimates and Forecasts, by Biomarkers (2020-2032) (USD Billion)
9.3.2.11.2 Switzerland Breast Cancer Liquid Biopsy Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
9.3.2.12 Austria
9.3.2.12.1 Austria Breast Cancer Liquid Biopsy Market Estimates and Forecasts, by Biomarkers (2020-2032) (USD Billion)
9.3.2.12.2 Austria Breast Cancer Liquid Biopsy Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
9.3.2.13 Rest of Western Europe
9.3.2.13.1 Rest of Western Europe Breast Cancer Liquid Biopsy Market Estimates and Forecasts, by Biomarkers (2020-2032) (USD Billion)
9.3.2.13.2 Rest of Western Europe Breast Cancer Liquid Biopsy Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
9.4 Asia Pacific
9.4.1 Trends Analysis
9.4.2 Asia Pacific Breast Cancer Liquid Biopsy Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
9.4.3 Asia Pacific Breast Cancer Liquid Biopsy Market Estimates and Forecasts, by Biomarkers (2020-2032) (USD Billion)
9.4.4 Asia Pacific Breast Cancer Liquid Biopsy Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
9.4.5 China
9.4.5.1 China Breast Cancer Liquid Biopsy Market Estimates and Forecasts, by Biomarkers (2020-2032) (USD Billion)
9.4.5.2 China Breast Cancer Liquid Biopsy Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
9.4.6 India
9.4.5.1 India Breast Cancer Liquid Biopsy Market Estimates and Forecasts, by Biomarkers (2020-2032) (USD Billion)
9.4.5.2 India Breast Cancer Liquid Biopsy Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
9.4.5 Japan
9.4.5.1 Japan Breast Cancer Liquid Biopsy Market Estimates and Forecasts, by Biomarkers (2020-2032) (USD Billion)
9.4.5.2 Japan Breast Cancer Liquid Biopsy Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
9.4.6 South Korea
9.4.6.1 South Korea Breast Cancer Liquid Biopsy Market Estimates and Forecasts, by Biomarkers (2020-2032) (USD Billion)
9.4.6.2 South Korea Breast Cancer Liquid Biopsy Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
9.4.7 Vietnam
9.4.7.1 Vietnam Breast Cancer Liquid Biopsy Market Estimates and Forecasts, by Biomarkers (2020-2032) (USD Billion)
9.2.7.2 Vietnam Breast Cancer Liquid Biopsy Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
9.4.8 Singapore
9.4.8.1 Singapore Breast Cancer Liquid Biopsy Market Estimates and Forecasts, by Biomarkers (2020-2032) (USD Billion)
9.4.8.2 Singapore Breast Cancer Liquid Biopsy Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
9.4.9 Australia
9.4.9.1 Australia Breast Cancer Liquid Biopsy Market Estimates and Forecasts, by Biomarkers (2020-2032) (USD Billion)
9.4.9.2 Australia Breast Cancer Liquid Biopsy Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
9.4.10 Rest of Asia Pacific
9.4.10.1 Rest of Asia Pacific Breast Cancer Liquid Biopsy Market Estimates and Forecasts, by Biomarkers (2020-2032) (USD Billion)
9.4.10.2 Rest of Asia Pacific Breast Cancer Liquid Biopsy Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
9.5 Middle East and Africa
9.5.1 Middle East
9.5.1.1 Trends Analysis
9.5.1.2 Middle East Breast Cancer Liquid Biopsy Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
9.5.1.3 Middle East Breast Cancer Liquid Biopsy Market Estimates and Forecasts, by Biomarkers (2020-2032) (USD Billion)
9.5.1.4 Middle East Breast Cancer Liquid Biopsy Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
9.5.1.5 UAE
9.5.1.5.1 UAE Breast Cancer Liquid Biopsy Market Estimates and Forecasts, by Biomarkers (2020-2032) (USD Billion)
9.5.1.5.2 UAE Breast Cancer Liquid Biopsy Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
9.5.1.6 Egypt
9.5.1.6.1 Egypt Breast Cancer Liquid Biopsy Market Estimates and Forecasts, by Biomarkers (2020-2032) (USD Billion)
9.5.1.6.2 Egypt Breast Cancer Liquid Biopsy Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
9.5.1.7 Saudi Arabia
9.5.1.7.1 Saudi Arabia Breast Cancer Liquid Biopsy Market Estimates and Forecasts, by Biomarkers (2020-2032) (USD Billion)
9.5.1.7.2 Saudi Arabia Breast Cancer Liquid Biopsy Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
9.5.1.8 Qatar
9.5.1.8.1 Qatar Breast Cancer Liquid Biopsy Market Estimates and Forecasts, by Biomarkers (2020-2032) (USD Billion)
9.5.1.8.2 Qatar Breast Cancer Liquid Biopsy Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
9.5.1.9 Rest of Middle East
9.5.1.9.1 Rest of Middle East Breast Cancer Liquid Biopsy Market Estimates and Forecasts, by Biomarkers (2020-2032) (USD Billion)
9.5.1.9.2 Rest of Middle East Breast Cancer Liquid Biopsy Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
9.5.2 Africa
9.5.2.1 Trends Analysis
9.5.2.2 Africa Breast Cancer Liquid Biopsy Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
9.5.2.3 Africa Breast Cancer Liquid Biopsy Market Estimates and Forecasts, by Biomarkers (2020-2032) (USD Billion)
9.5.2.4 Africa Breast Cancer Liquid Biopsy Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
9.5.2.5 South Africa
9.5.2.5.1 South Africa Breast Cancer Liquid Biopsy Market Estimates and Forecasts, by Biomarkers (2020-2032) (USD Billion)
9.5.2.5.2 South Africa Breast Cancer Liquid Biopsy Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
9.5.2.6 Nigeria
9.5.2.6.1 Nigeria Breast Cancer Liquid Biopsy Market Estimates and Forecasts, by Biomarkers (2020-2032) (USD Billion)
9.5.2.6.2 Nigeria Breast Cancer Liquid Biopsy Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
9.6 Latin America
9.6.1 Trends Analysis
9.6.2 Latin America Breast Cancer Liquid Biopsy Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
9.6.3 Latin America Breast Cancer Liquid Biopsy Market Estimates and Forecasts, by Biomarkers (2020-2032) (USD Billion)
9.6.4 Latin America Breast Cancer Liquid Biopsy Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
9.6.5 Brazil
9.6.5.1 Brazil Breast Cancer Liquid Biopsy Market Estimates and Forecasts, by Biomarkers (2020-2032) (USD Billion)
9.6.5.2 Brazil Breast Cancer Liquid Biopsy Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
9.6.6 Argentina
9.6.6.1 Argentina Breast Cancer Liquid Biopsy Market Estimates and Forecasts, by Biomarkers (2020-2032) (USD Billion)
9.6.6.2 Argentina Breast Cancer Liquid Biopsy Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
9.6.7 Colombia
9.6.7.1 Colombia Breast Cancer Liquid Biopsy Market Estimates and Forecasts, by Biomarkers (2020-2032) (USD Billion)
9.6.7.2 Colombia Breast Cancer Liquid Biopsy Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
9.6.8 Rest of Latin America
9.6.8.1 Rest of Latin America Breast Cancer Liquid Biopsy Market Estimates and Forecasts, by Biomarkers (2020-2032) (USD Billion)
9.6.8.2 Rest of Latin America Breast Cancer Liquid Biopsy Market Estimates and Forecasts, by Application (2020-2032) (USD Billion)
10. Company Profiles
10.1 The Menarini Group
10.1.1 Company Overview
10.1.2 Financial
10.1.3 Products/ Services Offered
10.1.4 SWOT Analysis
10.2 NeoGenomics Laboratories
10.2.1 Company Overview
10.2.2 Financial
10.2.3 Products/ Services Offered
10.2.4 SWOT Analysis
10.3 F. Hoffmann-La Roche Ltd.
10.3.1 Company Overview
10.3.2 Financial
10.3.3 Products/ Services Offered
10.3.4 SWOT Analysis
10.4 Myriad Genetics, Inc.
10.4.1 Company Overview
10.4.2 Financial
10.4.3 Products/ Services Offered
10.4.4 SWOT Analysis
10.5 Thermo Fisher Scientific, Inc.
10.5.1 Company Overview
10.5.2 Financial
10.5.3 Products/ Services Offered
10.5.4 SWOT Analysis
10.6 QIAGEN
10.6.1 Company Overview
10.6.2 Financial
10.6.3 Products/ Services Offered
10.6.4 SWOT Analysis
10.7 Biocept, Inc.
10.7.1 Company Overview
10.7.2 Financial
10.7.3 Products/ Services Offered
10.7.4 SWOT Analysis
10.8 Biocept, Inc.
10.8.1 Company Overview
10.8.2 Financial
10.8.3 Products/ Services Offered
10.8.4 SWOT Analysis
10.9 Fluxion Biosciences, Inc.
10.9.1 Company Overview
10.9.2 Financial
10.9.3 Products/ Services Offered
10.9.4 SWOT Analysis
10.10 Epic Sciences, Inc.
10.10.1 Company Overview
10.10.2 Financial
10.10.3 Products/ Services Offered
10.10.4 SWOT Analysis
11. Use Cases and Best Practices
12. Conclusion
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
Key Segments
By Biomarkers
Circulating Tumor Cells (CTCs)
Circulating Cell-Free DNA (cfDNA)
Extracellular Vesicles (EVs)
Other Circulating Biomarkers
By Application
Early Detection/Screening
Diagnosis
Treatment Selection
Monitoring
Request for Segment Customization as per your Business Requirement: Segment Customization Request
Regional Coverage:
North America
US
Canada
Mexico
Europe
Eastern Europe
Poland
Romania
Hungary
Turkey
Rest of Eastern Europe
Western Europe
Germany
France
UK
Italy
Spain
Netherlands
Switzerland
Austria
Rest of Western Europe
Asia Pacific
China
India
Japan
South Korea
Vietnam
Singapore
Australia
Rest of Asia Pacific
Middle East & Africa
Middle East
UAE
Egypt
Saudi Arabia
Qatar
Rest of Middle East
Africa
Nigeria
South Africa
Rest of Africa
Latin America
Brazil
Argentina
Colombia
Rest of Latin America
Request for Country Level Research Report: Country Level Customization Request
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
Detailed Volume Analysis
Criss-Cross segment analysis (e.g. Product X Application)
Competitive Product Benchmarking
Geographic Analysis
Additional countries in any of the regions
Customized Data Representation
Detailed analysis and profiling of additional market players
The Genome Editing Market size valued at USD 7.99 billion in 2023 and is expected to reach USD 32.72 billion by 2032 with a growing CAGR of 16.98% during the forecast period of 2024-2032.
The Functional Endoscopic Sinus Surgery Market Size was valued at USD 1.01 Billion in 2023, and is expected to reach USD 1.91 Billion by 2032, and grow at a CAGR of 7.66% over the Forecast Period of 2024-2032.
The liquid biopsy market size is projected to grow from USD 7.20 billion in 2023 to USD 21.78 billion by 2032, at a CAGR of 13.11% during 2024–2032.
The Clinical Workflow Solutions Market Size was valued at USD 11.07 billion in 2023 and will reach $32.71 billion by 2032, growing at a CAGR of 12.81% over the forecast period of 2024-2032.
The Epilepsy Surgery Market Size was valued at USD 1.20 billion in 2023 and is expected to reach USD 2.00 billion by 2032 and grow at a CAGR of 5.87% over the forecast period 2024-2032.
The Period Panties Market Size was valued at USD 111.40 Million in 2023 and is expected to reach USD 420.77 Million by 2032 and grow at a CAGR of 16.81% over the forecast period 2024-2032.
Hi! Click one of our member below to chat on Phone
© 2025 All Rights Reserved by SNS Insider Pvt Ltd
